UBS Group
COYA icon

UBS Group’s Coya Therapeutics COYA Stock Holding History

UBS Group’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$152K Buy
38,564
+3,529
+10% +$16.5K ﹤0.01% 6782
2025
Q4 		$203K Buy
35,035
+21,737
+163% +$132K ﹤0.01% 6573
2025
Q3 		$75.8K Sell
13,298
-1,829
-12% -$11.1K ﹤0.01% 7290
2025
Q2 		$87K Sell
15,127
-18,962
-56% -$110K ﹤0.01% 7348
2025
Q1 		$221K Sell
34,089
-8,937
-21% -$56.6K ﹤0.01% 6486
2024
Q4 		$247K Buy
+43,026
New +$293K ﹤0.01% 6326
2024
Q3 		– Sell
-10,696
Closed -$64.8K – 9564
2024
Q2 		$64.8K Buy
10,696
+10,096
+1,683% +$81.1K ﹤0.01% 6481
2024
Q1 		$5.95K Sell
600
-1,879
-76% -$14.7K ﹤0.01% 7495
2023
Q4 		$18.4K Buy
+2,479
New +$13.8K ﹤0.01% 7154
2023
Q3 		– Sell
-26,602
Closed -$108K – 9527
2023
Q2 		$108K Buy
26,602
+23,756
+835% +$110K ﹤0.01% 5948
2023
Q1 		$11.3K Buy
2,846
+1,631
+134% +$7.13K ﹤0.01% 7515
2022
Q4 		$5.76K Buy
+1,215
New +$5.66K ﹤0.01% 9133

Other funds holding COYA

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group's COYA Position: Q1 2026 in Review

UBS Group increased its Coya Therapeutics (COYA) stake by 10% in Q1 2026, buying an estimated $16.5K and bringing the position to 38,564 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #6782.

UBS Group first reported a position in COYA in Q4 2022 and has held it in 12 quarters since. The position peaked at $247K in Q4 2024. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

  • UBS Group held 38,564 shares of Coya Therapeutics worth $152K as of Q1 2026.
  • UBS Group bought 3,529 Coya Therapeutics shares in Q1 2026, an estimated $16.5K.
  • Coya Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6782 holding.
  • UBS Group first reported a position in Coya Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • UBS Group's Coya Therapeutics position peaked at $247K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.